drugset / Trial / NCT01564862

Efficacy of Lu AA21004 on Cognitive Dysfunction in Major Depressive Disorder

NCT01564862 ↗

Phase 2 Completed 602 enrolled Takeda
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate the effects of Lu AA21004, once daily (QD), on cognitive dysfunction in patients with major depressive disorder.

Timeline

Start
2012-04
Primary completion
2014-02
Completion
2014-02

Outcome

Met primary endpoint

registry analysis (superiority or other test); Vortioxetine (Lu AA21004) vs Placebo; p = 0.019; LS mean difference 1.75 (95% CI 0.28 to 3.21); ANCOVA; NCT01564862 ↗

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Duloxetine Small molecule 60 mg Oral
Subject Vortioxetine Unknown 10 mg Oral
Subject Vortioxetine Unknown 20 mg Oral